¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time series analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • discriminant analysis
    ÆÇº°ºÐ¼®
  • distributive analysis
    ºÐÆ÷ºÐ¼®
  • gastric analysis
    À§¾×°Ë»ç
  • gene analysis
    À¯ÀüÀںм®
  • image analysis
    ¿µ»óºÐ¼®
  • Kaplan-Meier analysis
    Ä«Çöõ-¸¶À̾îºÐ¼®
  • linkage analysis
    ¿¬°üºÐ¼®
  • multipoint linkage analysis
    ´ÙÁ¡¿¬°üºÐ¼®
  • multivariate analysis
    ´Ùº¯·®ºÐ¼®, ´Ù¿äÀκм®
  • meta-analysis
    ¸ÞŸºÐ¼®
  • nephelometric analysis
    ȥŹºÐ¼®
  • Northern blot analysis
    ³ë´øºí·ÔºÐ¼®
  • polarimetric analysis
    Æí±¤ºÐ¼®
  • precipitation analysis titration
    ħÀüºÐ¼®ÀûÁ¤
  • process analysis
    °øÁ¤ºÐ¼®, °úÁ¤ºÐ¼®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • reaction time
    ¹ÝÀÀ½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • repetition time
    ¹Ýº¹½Ã°£
  • scrub time
    ¼Õ¾Ä´Â½Ã°£
  • survival time
    »ýÁ¸±â°£
  • thrombin time
    Æ®·Òºó½Ã°£
  • transit time
    ÀüÀ̽ð£, Åë°ú½Ã°£
  • voiding time
    ¹è´¢½Ã°£
  • real time ultrasonography
    ½Ç½ÃÃÊÀ½ÆÄÃÔ¿µ¼ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cost-utility analysis
    ºñ¿ëÈ¿¿ëºÐ¼®
  • decision analysis
    ÀÇ»ç°áÁ¤ºÐ¼®
  • discriminant analysis
    ÆÇº°ºÐ¼®
  • distributive analysis
    ºÐÆ÷ºÐ¼®
  • gene analysis
    À¯ÀüÀںм®
  • image analysis
    ¿µ»óºÐ¼®
  • multivariate analysis
    ´Ùº¯·®ºÐ¼®, ´Ù¿äÀκм®
  • nephelometric analysis
    ȥŹºÐ¼®
  • path analysis
    °æ·ÎºÐ¼®
  • polarimetric analysis
    Æí±¤ºÐ¼®
  • principal component analysis
    ÁÖ¼ººÐºÐ¼®
  • process analysis
    °øÁ¤ºÐ¼®, °úÁ¤ºÐ¼®
  • qualitative analysis
    Á¤¼ººÐ¼®
  • quantitative analysis
    Á¤·®ºÐ¼®
  • radiochemical analysis
    ¹æ»çÈ­Çкм®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immunoglobulin subgroup analysis
    ¸é¿ª±Û·ÎºÒ¸°¾ÆÇüºÐ¼®
  • indirect analysis
    °£Á¢ºÐ¼®.
  • infrared spectroscopic analysis
    Àû¿Ü¼± ºÐ±¤ ºÐ¼®
  • inorganic analysis
    ¹«±âºÐ¼®(¡­ÝÂà°).
  • plasma analysis
    Ç÷ÀåºÐ¼®
  • polarimetric analysis
    Æí±¤ºÐ¼®(ÊÙËÓËÛ).
  • precipitation analysis =p. titration
    ħÀüºÐ¼®.
  • predictive analysis
    È¿°ú¿¹ÃøºÐ¼®
  • process analysis
    °øÁ¤ºÐ¼®(Ë­ËøËÓËÛ).
  • qualitative analysis
    Á¤¼ººÐ¼®(ïÒàõÝÂà°).
  • quantitative analysis
    Á¤·®ºÐ¼®(ïÒåÖÝÂà°).
  • radiometric analysis
    ¹æ»ç¼± ºÐ¼®
  • radiometric analysis
    ¹æ»çÃøÁ¤ºÐ¼®
  • rational analysis
    ½Ã¼ººÐ¼®(ãÆàõÝÂà°).
  • AUC : area under the concentration-time curve
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • analysis, antigen
    Ç׿øºÐ¼®
  • atomic absorption analysis
    ¿øÀÚÈí±¤ºÐ¼®.
  • binding displacement analysis
    °áÇÕº¯À§ºÐ¼®(Ì¿ùêܨêÈÝÂà°).
  • blood gas analysis
    Ç÷¾×°¡½ººÐ¼®.
  • case analysis
    Áõ·ÊºÐ¼® (¡­ºÐ¼®).
  • case analysis
    Áõ·ÊºÐ¼® (¡­ÝÂà°).
  • character analysis
    ¼º°ÝºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®, ¹«¸®ºÐ¼®
  • cluster analysis
    ±ÕÁÖ±ººÐ¼®(¡­ÝÂà°).
  • colo(u)rimetric analysis
    ºñ»öºÐ¼®¹ý(ÝïßäÝÂà°Ûö).
  • combustion analysis
    ¿¬¼ÒºÐ¼®(¡­ÝÂà°).
  • computer-assisted semen analysis (CASA )
    ÄÄÇ»ÅÍ º¸Á¶ Á¤¾×ºÐ¼®
  • computerized image analysis
    ÄÄÇ»ÅÍ ¿µ»ó ºÐ¼®
  • configurational analysis
    ¹èÄ¡ºÐ¼®(ÛÕöÇÝÂà°)
  • cost-benifit analysis
    ºñ¿ë-ÆíÀͺм®.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • time constant of a reaction
    ¹ÝÀÀ ½Ã°£»ó¼ö (ÚãëëãÁÊàßÈâ¦)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • transient time
    °úµµ±â ½Ã°£(ΦԤѢãÁÊà)
  • turnover time
    Àüȯ½Ã°£(ï®üµãÁÊà)
  • zero time binding DNA
    ¿µ½Ã(çÍãÁ) °áÇÕ(Ì¿ùê) DNA
  • zero time control
    ¿µ½Ã(çÍãÁ) ´ëÁ¶(ÓßðÎ)
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼® (üÀàõûùÝÂà°)
  • amino acid analysis
    ¾Æ¹Ì³ë»ê(ß«) ºÐ¼®(ÝÂà°)
  • analysis of variance
    ºÐ»êºÐ¼®(ÝÂߤÝÂà°)
  • conformational analysis
    ÀÔüÇüÅ ºÐ¼®(Ø¡ô÷û¡÷¾ÝÂà°)
  • control analysis
    ´ëÁ¶ ºÐ¼®(ÓßðÎÝÂà°)
  • covalent structure analysis
    °øÀ¯°áÇÕ ±¸Á¶ºÐ¼®(ÍìêóÌ¿ùêϰðãÝÂà°)
  • differential thermal analysis
    Â÷ ¿­ºÐ¼®(ó¬æðÝÂà°)
  • displacement analysis
    ´ëÄ¡ºÐ¼®(ÓÛöÇÝÂà°)
  • double isotope dilution analysis
    ÀÌÁß µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ì£ñìÔÒêÈêªáÈýüà·ÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • half-life; half-time
    ¹Ý°¨±â
  • intercostal real-time scanning
    ´Á°£ ½Ç½Ã°£½ºÄµ
  • inversion time
    ¿ªÀü½Ã°£
  • longitudinal relaxation time
    Á¾ÃàÀ̿Ͻð£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • polymerizing time
    ±»´Â½Ã°£, ÁßÇսð£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • pulmonary circulation time
    Æó¼øÈ¯½Ã°£
  • real time
    ½Ç½Ã°£, Áï½Ã
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • real time display
    ½Ç½Ã°£Ç¥½Ã
  • real time image
    ½Ç½Ã°£¿µ»ó
  • real time imaging
    ½Ç½Ã°£¿µ»ó±â¹ý
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time system
    ½Ç½Ã°£Ã¼°è
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PST pancreatic suppression test; paroxysmal supraventricular tachycardia; penicillin, streptomycin, and ...
RT radiologic technologist; radiotelemetry; radiotherapy; radium therapy; rapid tranquilization; reacti...
TE echo-time; expiratory time; tennis elbow; test ear; tetanus; tetracycline; threshold energy; thrombo...
TR recovery time; rectal temperature; repetition time; residual tuberculin; terminal repeat; tetrazoliu...
TTI tension-time index; time-tension index; timepto-intubation; torque-time interval; transtracheal insu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
BESA Brain electric source analysis
CoMFA Comparative Molecular Field Analysis
CADIA Computer assisted densitometric image analysis
CASA Computer assisted semen analysis
CASA Computer-Aided Sperm Analysis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • qualitative analysis
    Á¤¼º ºÐ¼®
    È­ÇÐ ºÐ¼®¹ý Áß¿¡¼­ ½Ã·á°¡ ¾î¶² ¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´ÂÁö ¾Ë¾Æ³»±â À§ÇÑ ºÐ¼®¹ýÀÇ ÃÑĪ. ÀϹÝÀûÀ¸·Î Á¤·® ºÐ¼®À» Çϱâ Àü¿¡ Á¤¼º ºÐ¼®À» ÇÏ°Ô µÈ´Ù. ¹°ÁúÀ» ±¸¼ºÇϰí ÀÖ´Â È­ÇÐÁ¾
  • script analysis
    °¢º» ºÐ¼®
    »çȸ¿¡ Âü¿©ÇÒ ¶§ Çൿ ¾ç»óÀÇ Æ²ÀÎ °¢º»ÀÌ ¸¸µé¾îÁö´Â °úÁ¤¿¡ ´ëÇÑ ºÐ¼®.
  • sequential analysis
    ¼øÂ÷Àû ºÐ¼®
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • space analysis
    °ø°£ ºÐ¼®
  • spectral analysis
    ½ºÆåÆ®·³ ºÐ¼®
    ¹°ÁúÀÇ ¹æÃâ ½ºÆåÆ®·³ ¶Ç´Â Èí¼ö ½ºÆåÆ®·³À» Á¶»çÇÏ¿©, ±× ¼Ó¿¡ ÀÖ´Â ¼ººÐ ¿ø¼Ò³ª È­ÇÕ¹°ÀÇ Á¾·ù¿Í ¾çÀ» ÆÇÁ¤ÇÏ´Â ¹æ¹ý. ºÐ±¤ È­ÇÐ ºÐ¼®À̶ó°íµµ ÇÑ´Ù. 19¼¼±â Áß¿±¿¡ R. ºÐÁ¨ÀÌ G. ۸£È÷È£ÇÁÀÇ Çù·ÂÀ» ¾ò¾î È®¸³½ÃŲ ½ÇÇè ±â¼úÀ̸ç, º¸ÅëÀÇ È­ÇÐ ºÐ¼®¿¡ ºñÇÏ¿© Á¶ÀÛÀÌ ºü¸£°í, ¼Ò·®ÀÇ ½Ã·á·Îµµ ºÐ¼®ÀÌ °¡´ÉÇÑ ÀÌÁ¡ÀÌ ÀÖ´Ù. ¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ °Í°ú, Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ °ÍÀÇ µÎ °¡Áö·Î Å©°Ô ³ª´­ ¼ö ÀÖ´Ù. ¡¼¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ¼®¡½ ¿øÀÚ¿¡¼­ ¹æÃâµÇ´Â ºûÀÇ ½ºÆåÆ®·³ÀÌ °¢ ¿ø¼Ò¿¡ µû¶ó °íÀ¯ÇÔÀ» ÀÌ¿ëÇÔÀ¸·Î½á, ½Ã·á¸¦ ¹ß±¤½ÃÄÑ ½ºÆåÆ®·³À» °Ë»çÇϰí, ¹Ì¸® Á¶»çÇÏ¿© µÐ Ç¥ÁØ ½Ã·áÀÇ ¹æÃâ ½ºÆåÆ®·³À» ±âÃÊ·Î ¼ººÐ ¿ø¼ÒÀÇ Á¾·ù³ª ¾çÀ» ¾Ë¾Æ³»´Â ¹æ¹ýÀÌ´Ù. °ËÃâÀÇ Á¤¹Ðµµ´Â ¿ø¼Ò¿¡ µû¶ó ´Ù¸£Áö¸¸, ÀϹÝÀûÀ¸·Î È­ÇÐ ºÐ¼®¿¡ ºñÇÏ¿© °¨µµ°¡ ³ô°í, ƯÈ÷ ±Ý¼Ó¿¡ ¹Ì·®À¸·Î ÇÔÀ¯µÇ¾î ÀÖ´Â ºÒ¼ø¹° ¿ø¼ÒÀÇ ¹ß°ßÀ̳ª Á¤·® µî¿¡´Â ÁÁÀº °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù. ½Ã·á¸¦ ¹ß±¤½ÃŰ´Â µ¥´Â º¸Åë ½Ã·á¸¦ ÇÑÂÊ ±ØÀ¸·Î ÇÏ´Â ¾ÆÅ© ¹æÀüÀ̳ª, ±âü »óÅÂÀÇ ½Ã·á¸¦ ¹æÀü°ü¿¡ ä¿ö¼­ ¹æÀü½ÃŰ´Â ¹æ¹ýÀÌ ÀÌ¿ëµÈ´Ù. ¾ËÄ®¸® ±Ý¼ÓÀ̳ª ¾ËÄ®¸®Åä ±Ý¼Ó¿¡ ´ëÇÑ ºÒ²É ¹ÝÀÀÀ» ÀÌ¿ëÇÑ ºÒ²É ½ÃÇèµµ ¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ °£´ÜÇÑ ºÐ±¤ ºÐ¼®À̶ó ÇÒ ¼ö ÀÖ´Ù. ¡¼Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ¼®¡½ ±âü³ª ¿ë¾×¿¡ ¿¬¼Ó ½ºÆåÆ®·³À» °¡Áø ºûÀ» Á¶»çÇϸé, ±× ¼Ó¿¡ Á¸ÀçÇϴ Ȭ ¿ø¼ÒÁúÀ̳ª È­ÇÕ¹°ÀÌ °¢°¢ ƯÀ¯ÇÑ ÆÄÀåÀÇ ºûÀ» ¼±ÅÃÀûÀ¸·Î Èí¼öÇϹǷÎ, Åõ°ú±¤ÀÇ ½ºÆåÆ®·³¿¡´Â ¹°ÁúÀÇ Á¾·ù¿¡ µû¶ó ƯÀ¯ÇÑ ¹è¿­À» °¡Áø Èí¼ö ¼±ÀÌ ³ªÅ¸³­´Ù. µû¶ó¼­, ¾î¶² ¾ç ¶Ç´Â µÎ²²ÀÇ ¼ø¼öÇÑ ¹°ÁúÀÇ Èí¼ö ½ºÆåÆ®·³À» ¸¹ÀÌ °®Ãß°í ÀÖÀ¸¸é, À̰ÍÀ» ±âÃÊ·Î ÇÏ¿© ¹ÌÁö ½Ã·áÀÇ Á¤¼º ºÐ¼®, ¾Ë°í ÀÖ´Â ½Ã·áÀÇ Á¤·® ºÐ¼®, ½Ã·á ¼Ó¿¡ ÀÖ´Â ºÒ¼ø¹°ÀÇ ¹ß°ß ¹× Á¤·®ÇÒ ¼ö ÀÖ´Ù. À̰ÍÀÌ Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ±¤ ºÐ¼®À̸ç, ƯÈ÷ ¿ë¾× ¼Ó¿¡ Á¸ÀçÇÏ´Â ºñŸ¹Î·ùÀÇ Á¤·® µîÀº ÀÌ ¹æ¹ýÀ» »ç¿ëÇÏ¸é ½±°Ô ¾Ë ¼ö ÀÖ´Ù. ºÐ±¤ ºÐ¼®Àº ½ºÆåÆ®·³ ºÐ¼®À̶ó°íµµ Çϴµ¥, ½ºÆåÆ®·³ ºÐ¼®À̶ó°í ÇÒ ¶§´Â ÀÌ»ó°ú °°Àº ºÐ¼® È­Çп¡ÀÇ ÀÀ¿ë ¿Ü¿¡, ¹°ÁúÀÇ ¹æÃâ ¶Ç´Â Èí¼ö ½ºÆåÆ®·³À» Á¤¹ÐÈ÷ ÃøÁ¤, ÇØ¼®ÇÏ¿© ¹°ÁúÀÇ ¿¡³ÊÁö ÁØÀ§, ÀüÀÌ È®·ü, ºÐÀÚÀÇ °áÇÕ °£°ÝÀ̳ª ºÐÀÚ ±¸Á¶ÀÇ °áÁ¤ µî¿¡µµ ÀÌ¿ëµÈ´Ù.
  • spectrophotometric analysis
    ºÐ±¤ ±¤µµ ºÐ¼®
  • statistic :

    statistical analysis

    Åë°èÀû ºÐ¼®
  • stress analysis
    ÀÀ·Â ºÐ¼®
  • synovial fluid analysis
    Ȱ¾× ºÐ¼®
  • thermal analysis
    ¿­ ºÐ¼®
  • urine analysis
    ¿ä °Ë»ç, ¼Òº¯ ºÐ¼®
    µ¿ÀǾî=urinalysis.
  • volumetric analysis
    ¿ë·® ºÐ¼®
  • water analysis
    ¼öºÐ¼®, ¼öÁú ºÐ¼®
  • wet analysis
    ½À½ÄºÐ¼®¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
median time to elimination <pharmacology> The time it takes one half of a drug to be eliminated from the body.
(09 Oct 1997)
repetition time In magnetic resonance imaging, the time between repetitions of the pulse sequence.
(05 Mar 2000)
rise time The time required for a pulse or echo to rise from 10% to 90% of its peak amplitude.
(05 Mar 2000)
P-H conduction time See: atrioventricular conduction.
(05 Mar 2000)
running time The time during which an activity (e.g., chromatography development) occurs.
(05 Mar 2000)
Russell's viper venom clotting time A clotting time determination performed on citrated platelet-poor plasma using Russell's viper venom as an activating agent. This allows activation of factor X directly without the need for other coagulation factors and is used to confirm factor X defects.
See: Stypven time test.
(05 Mar 2000)
circulation time The time taken for the blood to pass through a given circuit of the vascular system, e.g., the pulmonary or systemic circulation, from one arm to another, from arm to tongue, or from arm to lung; it is measured by the injection into an arm vein of a substance, such as sodium dehydrocholate, ether, fluorescein, histamine, or a radium salt, which can be detected when it arrives at another point in the vascular system.
(05 Mar 2000)
clot retraction time The time required for a blood clot to separate from the tube wall and express serum, usually completed in 18 to 24 hours, but retarded or absent in persons with thrombocytopenic purpura.
(05 Mar 2000)
clotting time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
coagulation time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
collision time <radiobiology> Typical time which passes between two consecutive collision events for a given particle. Inverse of the collision frequency, equal to the mean free path divided by the particle's velocity. In plasmas, the (Coulomb) collision time decreases with increasing density, and increases with increasing temperature.
(09 Oct 1997)
whole blood coagulation time Measurement of the time required by whole blood to produce a visible clot. Factors that could influence the test are all but III, vii, and xiii. Activation may be by contact with the glass tube or exposure to diatomaceous earth. Delay of onset of coagulation may be achieved by use of nonwettable plastic or silicone-coated glass tubes. It is used for monitoring heparin therapy and as a bedside screening test for deficiencies in the intrinsic coagulation pathway. "activated coagulation time" is sometimes referred to as act.
(12 Dec 1998)
confinement time <radiobiology> There are several types. The general definition is tau = [total]/[loss per unit time], hence Tau_E = [total energy]/[energy loss per unit time]. Tau_[E, N,.] is the amount of time the plasma is contained (for example, by magnetic fields) before its [energy (E), particles (N or P)] leak / dissipate away. The different types are, in general, similar but not equal. (N.B., Tau_E is NOT electron confinement time!)
(09 Oct 1997)
continuous time model <epidemiology> A model in which the system changes continuously over time. Derivatives (e.g. DY/dt ) are the mathematical formalism for describing such continuous change. The differential equation which embodies a model provides the values of these derivatives at any particular time point; calculus or a computer can then be used to move the state of the model forwards in time.
Continuous models have the advantage over discrete time models in that they are more amenable to algebraic manipulation, although they are slightly harder to implement on a computer.
The same as a differential equation model.
(05 Dec 1998)
half-time The time, in a first-order chemical (or enzymic) reaction, for half of the substance (substrate) to be converted or to disappear.
Compare: half-life.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • systems analysis
    (´É·ü,Á¤¹Ðµµ¸¦ ³ôÀ̱â À§ÇÑ) ½Ã½ºÅÛ ºÐ¼®
  • ultimate analysis
    ¿ø¼Ò ºÐ¼®
  • ultimate analysis
    ¿ø¼Ò ºÐ¼®
  • all the time
    ±×µ¿¾È Á×,(¹Ì)¾ðÁ¦³ª
  • any time
    ¾ðÁ¦µçÁö
  • at a time
    Çѹø¿¡,µ¿½Ã¿¡
  • at any time
    ¾ðÁ¦¶óµµ
  • at that time
    ±×¶§,±×´ç½Ã
  • at the same time
    µ¿½Ã¿¡
  • at this time of ~
    ~ÀÇ À̸¾¶§
  • behind time
    ´ÊÀº
  • bide one's time
    ÁÁÀº½Ã±â¸¦ ±â´Ù¸®´Ù
  • by that time
    ±×¶§±îÁö
  • by the time
    ±×¶§Âë¿¡
  • by-time
    ¿©°¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á